Please login to the form below

Not currently logged in
Email:
Password:

GalNAc

This page shows the latest GalNAc news and features for those working in and with pharma, biotech and healthcare.

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

This approach will be combined with a liver-targeting delivery technology in development at Pfizer that involves binding RNA drugs to the amno acid N-acetylgalactosamine (GalNAc). ... The deal gives WAVE scope to use GalNAc in certain projects that lie

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    targets. The overt focus on liver disease has led to one new system for delivering siRNA to the liver, called GalNAc. ... GalNAc uses a specific sugar group attached to chemically-modified siRNA to target liver cells.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics